Effect of vatinoxan co-administered with medetomidine on intraocular pressure and pupil diameter in healthy dogs

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62157124%3A16170%2F25%3A43882278" target="_blank" >RIV/62157124:16170/25:43882278 - isvavai.cz</a>

Výsledek na webu

<a href="http://chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://vetmed.agriculturejournals.cz/pdfs/vet/2025/12/01.pdf" target="_blank" >http://chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://vetmed.agriculturejournals.cz/pdfs/vet/2025/12/01.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.17221/47/2025-VETMED" target="_blank" >10.17221/47/2025-VETMED</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Effect of vatinoxan co-administered with medetomidine on intraocular pressure and pupil diameter in healthy dogs

Popis výsledku v původním jazyce

Medetomidine, an alpha-2 adrenoreceptor agonist, is used for sedation. This study aimed to determine the influence of the alpha-2 adrenoreceptor antagonist vatinoxan, co-administered with medetomidine, on healthy dogs’ intraocular pressure (IOP) and pupil diameter (PD). A prospective, randomised, masked clinical study was performed. A total of 40 conscious dogs were allocated to one of two groups: medetomidine 0.01 mg/kg with vatinoxan 0.2 mg/kg intravenously (MV-group, n = 20) or medetomidine 0.01 mg/kg intravenously (M-group, n = 20). The IOP, PD, heart rate, and mean arterial pressure were measured prior to baseline and 5, 10, and 20 min after drug administration. Data were analysed using one- and two-way repeated measures ANOVA or their non-parametric equivalents (P &lt; 0.05). No significant differences in IOP within or between groups were recorded. In the MV-group, PD remained unchanged compared to baseline. In the M-group, PD significantly (P = 0.007, P &lt; 0.001, P &lt; 0.001) decreased compared to baseline at all observation times. PD was significantly (P = 0.010, P &lt; 0.001, P &lt; 0.001) smaller in the M-group at all observation times compared to the MV-group. Vatinoxan co-administered with medetomidine, as well as medetomidine alone, did not significantly influence IOP. Vatinoxan with medetomidine did not affect PD, while medetomidine alone significantly reduced it.

Název v anglickém jazyce

Effect of vatinoxan co-administered with medetomidine on intraocular pressure and pupil diameter in healthy dogs

Popis výsledku anglicky

Medetomidine, an alpha-2 adrenoreceptor agonist, is used for sedation. This study aimed to determine the influence of the alpha-2 adrenoreceptor antagonist vatinoxan, co-administered with medetomidine, on healthy dogs’ intraocular pressure (IOP) and pupil diameter (PD). A prospective, randomised, masked clinical study was performed. A total of 40 conscious dogs were allocated to one of two groups: medetomidine 0.01 mg/kg with vatinoxan 0.2 mg/kg intravenously (MV-group, n = 20) or medetomidine 0.01 mg/kg intravenously (M-group, n = 20). The IOP, PD, heart rate, and mean arterial pressure were measured prior to baseline and 5, 10, and 20 min after drug administration. Data were analysed using one- and two-way repeated measures ANOVA or their non-parametric equivalents (P &lt; 0.05). No significant differences in IOP within or between groups were recorded. In the MV-group, PD remained unchanged compared to baseline. In the M-group, PD significantly (P = 0.007, P &lt; 0.001, P &lt; 0.001) decreased compared to baseline at all observation times. PD was significantly (P = 0.010, P &lt; 0.001, P &lt; 0.001) smaller in the M-group at all observation times compared to the MV-group. Vatinoxan co-administered with medetomidine, as well as medetomidine alone, did not significantly influence IOP. Vatinoxan with medetomidine did not affect PD, while medetomidine alone significantly reduced it.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

40301 - Veterinary science

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Veterinární medicína

ISSN

0375-8427

e-ISSN

1805-9392

Svazek periodika

70

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

5

Strana od-do

427-431

Kód UT WoS článku

001654806700001

EID výsledku v databázi Scopus

—